- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03952585
Radioterapia de-intensificata con chemioterapia (cisplatino) o immunoterapia (nivolumab) nel trattamento di pazienti con carcinoma orofaringeo in stadio iniziale, HPV-positivo, associato a non fumatori
Uno studio randomizzato di fase II/III di radioterapia de-intensificata per pazienti con carcinoma orofaringeo associato a non fumatori, P16-positivo in stadio iniziale
This phase II/III trial studies how well a reduced dose of radiation therapy works with nivolumab compared to cisplatin in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer that is early in its growth and may not have spread to other parts of the body (early-stage), and is not associated with smoking. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial is being done to see if a reduced dose of radiation therapy and nivolumab works as well as standard dose radiation therapy and cisplatin in treating patients with oropharyngeal cancer.
Panoramica dello studio
Stato
Condizioni
- Carcinoma orofaringeo a cellule squamose
- Carcinoma spinocellulare
- Carcinoma a cellule squamose basaloidi
- Carcinoma orofaringeo mediato da HPV (p16-positivo) stadio clinico I AJCC v8
- Carcinoma orofaringeo mediato da HPV (p16-positivo) stadio clinico II AJCC v8
- Carcinoma papillare a cellule squamose
- Carcinoma orofaringeo patologico in stadio I mediato da HPV (p16-positivo) AJCC v8
- Carcinoma orofaringeo in stadio patologico II HPV-mediato (p16-positivo) AJCC v8
Intervento / Trattamento
- Altro: Quality-of-Life Assessment
- Droga: Cisplatin
- Procedura: Biospecimen Collection
- Procedura: Computed Tomography
- Procedura: Magnetic Resonance Imaging
- Altro: Questionnaire Administration
- Procedura: Positron Emission Tomography
- Biologico: Nivolumab
- Radiazione: Intensity-Modulated Radiation Therapy
- Altro: Fludeoxyglucose F-18
- Procedura: Biopsy Procedure
- Radiazione: Image Guided Radiation Therapy
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To demonstrate non-inferiority in terms of progression-free survival (PFS) of concurrent reduced-dose radiation therapy (RT) with cisplatin or concurrent reduced-dose radiation therapy with nivolumab to the current standard of care (standard-dose RT with cisplatin). (Phase II) (Arm 2 [concurrent reduced-dose RT with cisplatin] was dropped after interim futility analysis in phase II.) II. To demonstrate non-inferiority in terms of progression-free survival (PFS) of concurrent reduced-dose radiation therapy (RT) with nivolumab to the current standard of care (standard-dose RT with cisplatin). (Phase II) III. To demonstrate co-primary endpoints of non-inferiority of PFS and superiority of quality of life (QOL) as measured by the MD Anderson Dysphagia Inventory (MDADI) of concurrent reduced-dose radiation with cisplatin or concurrent reduced-dose radiation with nivolumab to the current standard of care (standard-dose RT with cisplatin). (Phase III) (Arm 2 [concurrent reduced-dose RT with cisplatin] was dropped after interim futility analysis in phase II.) IV. To demonstrate co-primary endpoints of non-inferiority of PFS and superiority of quality of life (QOL) as measured by the MD Anderson Dysphagia Inventory [MDADI] of concurrent reduced-dose radiation with nivolumab to the current standard of care (standard-dose RT with cisplatin). (Phase III)
SECONDARY OBJECTIVES:
I. To compare patterns of failure (local and regional relapse versus distant) and overall survival between the experimental arm and the control arm.
II. To assess long term PFS, overall survival, and toxicity between the experimental arm and the control arm.
III. To determine acute and late toxicity profiles as measured by the Common Terminology Criteria for Adverse Events (CTCAE).
IV. To explore the symptomatic adverse events (AEs) for tolerability of each treatment arm as measured by the Patient-Reported Outcomes (PRO)-CTCAE.
V. To compare changes in patient-reported outcomes (Hearing Handicap Inventory for Adults-Screening [HHIA-S], European Organization for Research and Treatment of Cancer [EORTC]-Quality of Life Questionnaire [QLQ]30) between the experimental arm and the control arm.
VI. To assess the association of fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) at baseline with locoregional control and PFS.
VII. To estimate the negative predictive value of the 12-14 weeks post-radiation therapy (RT) FDG-PET/CT in terms of locoregional control rates and PFS rates at 1 and 2 years.
EXPLORATORY OBJECTIVES:
I. To collect blood and tissue specimens for future translation research. II. To optimize radiotherapy treatment plan quality assurance methodology for radiotherapy planning and imaging.
III. To compare changes in patient-reported outcomes (European Quality of Life Five Dimension Five Level Scale [EQ-5D-5L]) between the experimental arm and the control arm.
IV. To collect Modified Barium Swallow (MBS) data for future review and analysis.
OUTLINE:
PHASE II: Patients are randomized to 1 of 3 arms.
ARM I: Patients undergo standard dose RT as 70 Gy intensity modulated radiation therapy (IMRT) or image-guided radiation therapy (IGRT) over 6 fractions per week and receive 100 mg/m^2/day cisplatin intravenously (IV) over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive fludeoxyglucose F-18 (FDG) and undergo positron emission tomography (PET)/computed tomography (CT) or CT during screening and during follow up, and undergo magnetic resonance imaging (MRI) during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
ARM II (CLOSED TO ACCRUAL 03-FEB-2023): Patients undergo reduced dose RT as 60 Gy IMRT or IGRT once daily (QD) over 5 fractions per week and receive 100 mg/m^2/day cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
ARM III: Beginning 1 week prior to radiation, patients receive 240 mg fixed dose nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks (14 days) for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo reduced dose RT as 60 Gy IMRT or IGRT over 6 fractions per week for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
PHASE III: Patients are randomized to Arm I and/or Arm III.
After completion of study treatment, patients are followed up at 12-14 weeks, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Arizona
-
Gilbert, Arizona, Stati Uniti, 85234
- Banner MD Anderson Cancer Center
-
Tucson, Arizona, Stati Uniti, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Stati Uniti, 85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Antioch, California, Stati Uniti, 94531
- Kaiser Permanente-Deer Valley Medical Center
-
Arroyo Grande, California, Stati Uniti, 93420
- PCR Oncology
-
Auburn, California, Stati Uniti, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Stati Uniti, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Bakersfield, California, Stati Uniti, 93301
- AIS Cancer Center at San Joaquin Community Hospital
-
Beverly Hills, California, Stati Uniti, 90211
- Tower Cancer Research Foundation
-
Cameron Park, California, Stati Uniti, 95682
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park
-
Duarte, California, Stati Uniti, 91010
- City of Hope Comprehensive Cancer Center
-
Dublin, California, Stati Uniti, 94568
- Kaiser Permanente Dublin
-
Encinitas, California, Stati Uniti, 92024
- UC San Diego Health System - Encinitas
-
Fremont, California, Stati Uniti, 94538
- Kaiser Permanente-Fremont
-
Fresno, California, Stati Uniti, 93720
- Kaiser Permanente-Fresno
-
Fresno, California, Stati Uniti, 93720
- Fresno Cancer Center
-
Irvine, California, Stati Uniti, 92618
- City of Hope at Irvine Lennar
-
La Jolla, California, Stati Uniti, 92093
- UC San Diego Moores Cancer Center
-
Lancaster, California, Stati Uniti, 93534
- City of Hope Antelope Valley
-
Los Angeles, California, Stati Uniti, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Stati Uniti, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Stati Uniti, 90033
- Los Angeles General Medical Center
-
Marysville, California, Stati Uniti, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Stati Uniti, 95356
- Kaiser Permanente-Modesto
-
Mountain View, California, Stati Uniti, 94040
- Palo Alto Medical Foundation-Camino Division
-
Oakland, California, Stati Uniti, 94611
- Kaiser Permanente-Oakland
-
Oakland, California, Stati Uniti, 94611
- Kaiser Permanente Oakland-Broadway
-
Palo Alto, California, Stati Uniti, 94304
- Stanford Cancer Institute Palo Alto
-
Palo Alto, California, Stati Uniti, 94301
- Palo Alto Medical Foundation Health Care
-
Rancho Cordova, California, Stati Uniti, 95670
- Kaiser Permanente-Rancho Cordova Cancer Center
-
Redwood City, California, Stati Uniti, 94063
- Kaiser Permanente- Marshall Medical Offices
-
Richmond, California, Stati Uniti, 94801
- Kaiser Permanente-Richmond
-
Rohnert Park, California, Stati Uniti, 94928
- Rohnert Park Cancer Center
-
Roseville, California, Stati Uniti, 95678
- The Permanente Medical Group-Roseville Radiation Oncology
-
Roseville, California, Stati Uniti, 95661
- Kaiser Permanente-Roseville
-
Roseville, California, Stati Uniti, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Stati Uniti, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Stati Uniti, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Stati Uniti, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Stati Uniti, 95814
- Kaiser Permanente Downtown Commons
-
Sacramento, California, Stati Uniti, 95823
- Kaiser Permanente-South Sacramento
-
Sacramento, California, Stati Uniti, 95823
- South Sacramento Cancer Center
-
San Diego, California, Stati Uniti, 92134
- Naval Medical Center -San Diego
-
San Diego, California, Stati Uniti, 92103
- UC San Diego Medical Center - Hillcrest
-
San Francisco, California, Stati Uniti, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Stati Uniti, 94158
- UCSF Medical Center-Mission Bay
-
San Jose, California, Stati Uniti, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Jose, California, Stati Uniti, 95124
- Stanford Cancer Center South Bay
-
San Leandro, California, Stati Uniti, 94577
- Kaiser Permanente San Leandro
-
San Luis Obispo, California, Stati Uniti, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
San Rafael, California, Stati Uniti, 94903
- Kaiser San Rafael-Gallinas
-
Santa Clara, California, Stati Uniti, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, Stati Uniti, 95403
- Kaiser Permanente-Santa Rosa
-
South Pasadena, California, Stati Uniti, 91030
- City of Hope South Pasadena
-
South San Francisco, California, Stati Uniti, 94080
- Kaiser Permanente Cancer Treatment Center
-
South San Francisco, California, Stati Uniti, 94080
- Kaiser Permanente-South San Francisco
-
Stockton, California, Stati Uniti, 95210
- Kaiser Permanente-Stockton
-
Sunnyvale, California, Stati Uniti, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Torrance, California, Stati Uniti, 90509
- Torrance Memorial Medical Center
-
Torrance, California, Stati Uniti, 90505
- Torrance Memorial Physician Network - Cancer Care
-
Torrance, California, Stati Uniti, 90503
- City of Hope South Bay
-
Upland, California, Stati Uniti, 91786
- City of Hope Upland
-
Vacaville, California, Stati Uniti, 95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo, California, Stati Uniti, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Stati Uniti, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Rocky Mountain Regional VA Medical Center
-
Aurora, Colorado, Stati Uniti, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, Stati Uniti, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, Stati Uniti, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Stati Uniti, 80907
- Rocky Mountain Cancer Centers-Penrose
-
Colorado Springs, Colorado, Stati Uniti, 80920
- Memorial Hospital North
-
Denver, Colorado, Stati Uniti, 80210
- AdventHealth Porter
-
Fort Collins, Colorado, Stati Uniti, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Stati Uniti, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Stati Uniti, 80631
- UCHealth Greeley Hospital
-
Littleton, Colorado, Stati Uniti, 80122
- AdventHealth Littleton
-
Loveland, Colorado, Stati Uniti, 80538
- Medical Center of the Rockies
-
Parker, Colorado, Stati Uniti, 80138
- AdventHealth Parker
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06102
- Hartford Hospital
-
-
Delaware
-
Newark, Delaware, Stati Uniti, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Stati Uniti, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Stati Uniti, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Stati Uniti, 19718
- Christiana Care Health System-Christiana Hospital
-
-
Florida
-
Coral Gables, Florida, Stati Uniti, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Coral Springs, Florida, Stati Uniti, 33065
- UM Sylvester Comprehensive Cancer Center at Coral Springs
-
Deerfield Beach, Florida, Stati Uniti, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Jupiter, Florida, Stati Uniti, 33458
- Jupiter Medical Center
-
Miami, Florida, Stati Uniti, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Stati Uniti, 33176
- Miami Cancer Institute
-
Miami, Florida, Stati Uniti, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Orlando, Florida, Stati Uniti, 32806
- Orlando Health Cancer Institute
-
Tampa, Florida, Stati Uniti, 33612
- Moffitt Cancer Center
-
Tampa, Florida, Stati Uniti, 33607
- Moffitt Cancer Center-International Plaza
-
Tampa, Florida, Stati Uniti, 33612
- Moffitt Cancer Center - McKinley Campus
-
Wesley Chapel, Florida, Stati Uniti, 33544
- Moffitt Cancer Center at Wesley Chapel
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Stati Uniti, 30303
- Grady Health System
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Stati Uniti, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Stati Uniti, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Stati Uniti, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Stati Uniti, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Stati Uniti, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Stati Uniti, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Stati Uniti, 96817
- Kuakini Medical Center
-
Honolulu, Hawaii, Stati Uniti, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Stati Uniti, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Stati Uniti, 96819
- Kaiser Permanente Moanalua Medical Center
-
Lihue, Hawaii, Stati Uniti, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Stati Uniti, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Stati Uniti, 96701
- Pali Momi Medical Center
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Stati Uniti, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Stati Uniti, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, Stati Uniti, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stati Uniti, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Stati Uniti, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora, Illinois, Stati Uniti, 60504
- Rush-Copley Medical Center
-
Barrington, Illinois, Stati Uniti, 60010
- Advocate Good Shepherd Hospital
-
Bloomington, Illinois, Stati Uniti, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Stati Uniti, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Stati Uniti, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Stati Uniti, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
Chicago, Illinois, Stati Uniti, 60657
- Advocate Illinois Masonic Medical Center
-
Chicago, Illinois, Stati Uniti, 60612
- Rush MD Anderson Cancer Center
-
Crystal Lake, Illinois, Stati Uniti, 60014
- AMG Crystal Lake - Oncology
-
DeKalb, Illinois, Stati Uniti, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Stati Uniti, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stati Uniti, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Downers Grove, Illinois, Stati Uniti, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Stati Uniti, 62401
- Crossroads Cancer Center
-
Elgin, Illinois, Stati Uniti, 60123
- Advocate Sherman Hospital
-
Eureka, Illinois, Stati Uniti, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Stati Uniti, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Stati Uniti, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Stati Uniti, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Stati Uniti, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Stati Uniti, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Stati Uniti, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Stati Uniti, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Stati Uniti, 61455
- Illinois CancerCare-Macomb
-
Maywood, Illinois, Stati Uniti, 60153
- Loyola University Medical Center
-
O'Fallon, Illinois, Stati Uniti, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Stati Uniti, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Stati Uniti, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Stati Uniti, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Stati Uniti, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Stati Uniti, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Stati Uniti, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Stati Uniti, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Stati Uniti, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Stati Uniti, 61114
- UW Health Carbone Cancer Center Rockford
-
Shiloh, Illinois, Stati Uniti, 62269
- Memorial Hospital East
-
Springfield, Illinois, Stati Uniti, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stati Uniti, 62702
- Springfield Clinic
-
Springfield, Illinois, Stati Uniti, 62781
- Springfield Memorial Hospital
-
Warrenville, Illinois, Stati Uniti, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington, Illinois, Stati Uniti, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Carmel, Indiana, Stati Uniti, 46032
- IU Health North Hospital
-
Indianapolis, Indiana, Stati Uniti, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Stati Uniti, 46202
- Sidney and Lois Eskenazi Hospital
-
-
Iowa
-
Clive, Iowa, Stati Uniti, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Stati Uniti, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Stati Uniti, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Stati Uniti, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stati Uniti, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stati Uniti, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Stati Uniti, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Stati Uniti, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stati Uniti, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
West Des Moines, Iowa, Stati Uniti, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Stati Uniti, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- University of Kansas Cancer Center
-
Lawrence, Kansas, Stati Uniti, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Stati Uniti, 66061
- The University of Kansas Cancer Center - Olathe
-
Overland Park, Kansas, Stati Uniti, 66210
- University of Kansas Cancer Center-Overland Park
-
Salina, Kansas, Stati Uniti, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Stati Uniti, 66606
- University of Kansas Health System Saint Francis Campus
-
Westwood, Kansas, Stati Uniti, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Stati Uniti, 40202
- Norton Hospital Pavilion and Medical Campus
-
Louisville, Kentucky, Stati Uniti, 40202
- The James Graham Brown Cancer Center at University of Louisville
-
Louisville, Kentucky, Stati Uniti, 40241
- Norton Brownsboro Hospital and Medical Campus
-
Louisville, Kentucky, Stati Uniti, 40202
- Jewish Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Stati Uniti, 70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge, Louisiana, Stati Uniti, 70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge, Louisiana, Stati Uniti, 70808
- Our Lady of the Lake Physician Group
-
Metairie, Louisiana, Stati Uniti, 70006
- East Jefferson General Hospital
-
-
Maine
-
Bath, Maine, Stati Uniti, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Biddeford, Maine, Stati Uniti, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Portland, Maine, Stati Uniti, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Stati Uniti, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Stati Uniti, 04073
- MaineHealth Cancer Care Center of York County
-
Sanford, Maine, Stati Uniti, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Stati Uniti, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Stati Uniti, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Stati Uniti, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bel Air, Maryland, Stati Uniti, 21014
- UM Upper Chesapeake Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Stati Uniti, 02118
- Boston Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Bay City, Michigan, Stati Uniti, 48706
- McLaren Cancer Institute-Bay City
-
Brighton, Michigan, Stati Uniti, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Stati Uniti, 48114
- Trinity Health Medical Center - Brighton
-
Brownstown, Michigan, Stati Uniti, 48183
- Henry Ford Cancer Institute-Downriver
-
Canton, Michigan, Stati Uniti, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Stati Uniti, 48188
- Trinity Health Medical Center - Canton
-
Caro, Michigan, Stati Uniti, 48723
- Caro Cancer Center
-
Chelsea, Michigan, Stati Uniti, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Stati Uniti, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Stati Uniti, 48346
- McLaren Cancer Institute-Clarkston
-
Clinton Township, Michigan, Stati Uniti, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Stati Uniti, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, Stati Uniti, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Stati Uniti, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Stati Uniti, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Stati Uniti, 48532
- McLaren Cancer Institute-Flint
-
Flint, Michigan, Stati Uniti, 48532
- Singh and Arora Hematology Oncology PC
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Lansing, Michigan, Stati Uniti, 48912
- Mid-Michigan Physicians-Lansing
-
Lansing, Michigan, Stati Uniti, 48910
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Lansing, Michigan, Stati Uniti, 48912
- University of Michigan Health - Sparrow Lansing
-
Lapeer, Michigan, Stati Uniti, 48446
- McLaren Cancer Institute-Lapeer Region
-
Livonia, Michigan, Stati Uniti, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Marlette, Michigan, Stati Uniti, 48453
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Mount Clemens, Michigan, Stati Uniti, 48043
- McLaren Cancer Institute-Macomb
-
Niles, Michigan, Stati Uniti, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Novi, Michigan, Stati Uniti, 48377
- Henry Ford Medical Center-Columbus
-
Petoskey, Michigan, Stati Uniti, 49770
- McLaren Cancer Institute-Northern Michigan
-
Port Huron, Michigan, Stati Uniti, 48060
- McLaren-Port Huron
-
Saginaw, Michigan, Stati Uniti, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Stati Uniti, 48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph, Michigan, Stati Uniti, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Stati Uniti, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Shelby, Michigan, Stati Uniti, 48315
- Henry Ford Macomb Health Center - Shelby Township
-
Tawas City, Michigan, Stati Uniti, 48764
- MyMichigan Medical Center Tawas
-
West Bloomfield, Michigan, Stati Uniti, 48322
- Henry Ford West Bloomfield Hospital
-
West Branch, Michigan, Stati Uniti, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Stati Uniti, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Stati Uniti, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Stati Uniti, 56601
- Sanford Joe Lueken Cancer Center
-
Brainerd, Minnesota, Stati Uniti, 56401
- Essentia Health Saint Joseph's Medical Center
-
Deer River, Minnesota, Stati Uniti, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Stati Uniti, 55805
- Essentia Health Cancer Center
-
Duluth, Minnesota, Stati Uniti, 55805
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Stati Uniti, 55805
- Miller-Dwan Hospital
-
Hibbing, Minnesota, Stati Uniti, 55746
- Essentia Health Hibbing Clinic
-
Saint Cloud, Minnesota, Stati Uniti, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Sandstone, Minnesota, Stati Uniti, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Stati Uniti, 55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Cape Girardeau, Missouri, Stati Uniti, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Stati Uniti, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Stati Uniti, 63141
- Siteman Cancer Center at West County Hospital
-
Farmington, Missouri, Stati Uniti, 63640
- Parkland Health Center - Farmington
-
Joplin, Missouri, Stati Uniti, 64804
- Freeman Health System
-
Kansas City, Missouri, Stati Uniti, 64154
- University of Kansas Cancer Center - North
-
Lee's Summit, Missouri, Stati Uniti, 64064
- University of Kansas Cancer Center - Lee's Summit
-
North Kansas City, Missouri, Stati Uniti, 64116
- University of Kansas Cancer Center at North Kansas City Hospital
-
Rolla, Missouri, Stati Uniti, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Stati Uniti, 65401
- Phelps Health Delbert Day Cancer Institute
-
Springfield, Missouri, Stati Uniti, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Stati Uniti, 63129
- Siteman Cancer Center-South County
-
-
Montana
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Stati Uniti, 59405
- Benefis Sletten Cancer Institute
-
-
Nebraska
-
Kearney, Nebraska, Stati Uniti, 68847
- CHI Health Good Samaritan
-
Omaha, Nebraska, Stati Uniti, 68198
- University of Nebraska Medical Center
-
-
Nevada
-
Reno, Nevada, Stati Uniti, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Rutgers Cancer Institute of New Jersey
-
Toms River, New Jersey, Stati Uniti, 08755
- Community Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87109
- New Mexico Oncology Hematology Consultants
-
Albuquerque, New Mexico, Stati Uniti, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Canandaigua, New York, Stati Uniti, 14424
- Sands Cancer Center
-
Dansville, New York, Stati Uniti, 14437
- Noyes Memorial Hospital/Myers Cancer Center
-
Oswego, New York, Stati Uniti, 13126
- Upstate Cancer Center at Oswego
-
Rochester, New York, Stati Uniti, 14642
- University of Rochester
-
Rochester, New York, Stati Uniti, 14620
- Highland Hospital
-
Stony Brook, New York, Stati Uniti, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Stati Uniti, 13210
- State University of New York Upstate Medical University
-
Syracuse, New York, Stati Uniti, 13215
- SUNY Upstate Medical Center-Community Campus
-
Verona, New York, Stati Uniti, 13478
- Upstate Cancer Center at Verona
-
Webster, New York, Stati Uniti, 14580
- Wilmot Cancer Institute at Webster
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Stati Uniti, 28204
- Novant Health Presbyterian Medical Center
-
Charlotte, North Carolina, Stati Uniti, 28210
- Atrium Health Pineville/LCI-Pineville
-
Charlotte, North Carolina, Stati Uniti, 28262
- Atrium Health University City/LCI-University
-
Charlotte, North Carolina, Stati Uniti, 28277
- Levine Cancer Institute-Ballantyne
-
Clemmons, North Carolina, Stati Uniti, 27012
- Wake Forest University at Clemmons
-
Concord, North Carolina, Stati Uniti, 28025
- Atrium Health Cabarrus/LCI-Concord
-
Gastonia, North Carolina, Stati Uniti, 28054
- CaroMont Regional Medical Center
-
Greenville, North Carolina, Stati Uniti, 27834
- East Carolina University
-
Huntersville, North Carolina, Stati Uniti, 28078
- Novant Health Cancer Institute - Huntersville
-
Huntersville, North Carolina, Stati Uniti, 28078
- Novant Health Presbyterian Medical Center Huntersville
-
Kernersville, North Carolina, Stati Uniti, 27284
- Novant Health Cancer Institute - Kernersville
-
Matthews, North Carolina, Stati Uniti, 28105
- Novant Health Cancer Institute - Matthews
-
Monroe, North Carolina, Stati Uniti, 28112
- Atrium Health Union/LCI-Union
-
Mooresville, North Carolina, Stati Uniti, 28117
- Novant Health Cancer Institute - Mooresville
-
Mount Airy, North Carolina, Stati Uniti, 27030
- Novant Health Cancer Institute - Mount Airy
-
North Wilkesboro, North Carolina, Stati Uniti, 28659
- Novant Health Cancer Institute - Wilkesboro
-
Pinehurst, North Carolina, Stati Uniti, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Salisbury, North Carolina, Stati Uniti, 28144
- Novant Health Cancer Institute - Rowan
-
Statesville, North Carolina, Stati Uniti, 28625
- Novant Health Cancer Institute - Statesville
-
Statesville, North Carolina, Stati Uniti, 28677
- Wake Forest Baptist Health - Hematology Oncology - Statesville
-
Supply, North Carolina, Stati Uniti, 28462
- Novant Cancer Institute Radiation Oncology - Supply
-
Thomasville, North Carolina, Stati Uniti, 27360
- Novant Health Cancer Institute - Thomasville
-
Wilkesboro, North Carolina, Stati Uniti, 28659
- Wake Forest Baptist Health - Wilkes Medical Center
-
Wilmington, North Carolina, Stati Uniti, 28401
- Novant Health New Hanover Regional Medical Center
-
Wilmington, North Carolina, Stati Uniti, 28401
- Novant Health Cancer Institute Radiation Oncology - Wilmington
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Wake Forest University Health Sciences
-
Winston-Salem, North Carolina, Stati Uniti, 27103
- Novant Health Forsyth Medical Center
-
-
North Dakota
-
Bismarck, North Dakota, Stati Uniti, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Stati Uniti, 44304
- Summa Health System - Akron Campus
-
Avon, Ohio, Stati Uniti, 44011
- UH Seidman Cancer Center at UH Avon Health Center
-
Barberton, Ohio, Stati Uniti, 44203
- Summa Health System - Barberton Campus
-
Chardon, Ohio, Stati Uniti, 44024
- Geauga Hospital
-
Cincinnati, Ohio, Stati Uniti, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Stati Uniti, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Stati Uniti, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, Stati Uniti, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Stati Uniti, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Stati Uniti, 43210
- Ohio State University Comprehensive Cancer Center
-
Mansfield, Ohio, Stati Uniti, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Mayfield Heights, Ohio, Stati Uniti, 44124
- Hillcrest Hospital Cancer Center
-
Medina, Ohio, Stati Uniti, 44256
- Summa Health Medina Medical Center
-
Mentor, Ohio, Stati Uniti, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Middleburg Heights, Ohio, Stati Uniti, 44130
- UH Seidman Cancer Center at Southwest General Hospital
-
Parma, Ohio, Stati Uniti, 44129
- University Hospitals Parma Medical Center
-
Perrysburg, Ohio, Stati Uniti, 43551
- Mercy Health - Perrysburg Hospital
-
Ravenna, Ohio, Stati Uniti, 44266
- University Hospitals Portage Medical Center
-
Sandusky, Ohio, Stati Uniti, 44870
- North Coast Cancer Care
-
Strongsville, Ohio, Stati Uniti, 44136
- Cleveland Clinic Cancer Center Strongsville
-
Sylvania, Ohio, Stati Uniti, 43560
- ProMedica Flower Hospital
-
Toledo, Ohio, Stati Uniti, 43623
- Mercy Health - Saint Anne Hospital
-
Toledo, Ohio, Stati Uniti, 43608
- Mercy Health - Saint Vincent Hospital
-
Toledo, Ohio, Stati Uniti, 43623
- Mercy Health Sylvania Radiation Oncology Center
-
West Chester, Ohio, Stati Uniti, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westlake, Ohio, Stati Uniti, 44145
- UH Seidman Cancer Center at Saint John Medical Center
-
Westlake, Ohio, Stati Uniti, 44145
- UHHS-Westlake Medical Center
-
Wooster, Ohio, Stati Uniti, 44691
- Cleveland Clinic Wooster Family Health and Surgery Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Stati Uniti, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Stati Uniti, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Stati Uniti, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Stati Uniti, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Stati Uniti, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Stati Uniti, 97225
- Providence Saint Vincent Medical Center
-
Portland, Oregon, Stati Uniti, 97227
- Kaiser Permanente Northwest
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Altoona, Pennsylvania, Stati Uniti, 16601
- UPMC Altoona
-
Beaver, Pennsylvania, Stati Uniti, 15009
- UPMC-Heritage Valley Health System Beaver
-
Carlisle, Pennsylvania, Stati Uniti, 17015
- Carlisle Regional Cancer Center
-
Chadds Ford, Pennsylvania, Stati Uniti, 19317
- Christiana Care Health System-Concord Health Center
-
Chambersburg, Pennsylvania, Stati Uniti, 17201
- Chambersburg Hospital
-
Danville, Pennsylvania, Stati Uniti, 17822
- Geisinger Medical Center
-
East Norriton, Pennsylvania, Stati Uniti, 19401
- Fox Chase Cancer Center - East Norriton Hospital Outpatient Center
-
Ephrata, Pennsylvania, Stati Uniti, 17522
- Ephrata Cancer Center
-
Erie, Pennsylvania, Stati Uniti, 16505
- UPMC Hillman Cancer Center Erie
-
Farrell, Pennsylvania, Stati Uniti, 16121
- UPMC Cancer Center at UPMC Horizon
-
Furlong, Pennsylvania, Stati Uniti, 18925
- Fox Chase Cancer Center Buckingham
-
Gettysburg, Pennsylvania, Stati Uniti, 17325
- Adams Cancer Center
-
Greensburg, Pennsylvania, Stati Uniti, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Harrisburg, Pennsylvania, Stati Uniti, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Hershey, Pennsylvania, Stati Uniti, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Johnstown, Pennsylvania, Stati Uniti, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
Lewisburg, Pennsylvania, Stati Uniti, 17837
- Geisinger Medical Oncology-Lewisburg
-
Lewistown, Pennsylvania, Stati Uniti, 17044
- Lewistown Hospital
-
McKeesport, Pennsylvania, Stati Uniti, 15132
- UPMC Cancer Center at UPMC McKeesport
-
Mechanicsburg, Pennsylvania, Stati Uniti, 17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville, Pennsylvania, Stati Uniti, 15146
- Forbes Hospital
-
Monroeville, Pennsylvania, Stati Uniti, 15146
- UPMC Cancer Center - Monroeville
-
Moon Township, Pennsylvania, Stati Uniti, 15108
- UPMC Hillman Cancer Center in Coraopolis
-
Philadelphia, Pennsylvania, Stati Uniti, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Stati Uniti, 19114
- Jefferson Torresdale Hospital
-
Philadelphia, Pennsylvania, Stati Uniti, 19140
- Temple University Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213
- UPMC-Magee Womens Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- UPMC-Shadyside Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, Stati Uniti, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Pottsville, Pennsylvania, Stati Uniti, 17901
- Geisinger Cancer Services-Pottsville
-
Seneca, Pennsylvania, Stati Uniti, 16346
- UPMC Cancer Center at UPMC Northwest
-
Uniontown, Pennsylvania, Stati Uniti, 15401
- UPMC Uniontown Hospital Radiation Oncology
-
Washington, Pennsylvania, Stati Uniti, 15301
- UPMC Washington Hospital Radiation Oncology
-
West Reading, Pennsylvania, Stati Uniti, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Stati Uniti, 15090
- Wexford Health and Wellness Pavilion
-
Wilkes-Barre, Pennsylvania, Stati Uniti, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
Williamsport, Pennsylvania, Stati Uniti, 17754
- Divine Providence Hospital
-
Willow Grove, Pennsylvania, Stati Uniti, 19090
- Asplundh Cancer Pavilion
-
York, Pennsylvania, Stati Uniti, 17403
- WellSpan Health-York Cancer Center
-
York, Pennsylvania, Stati Uniti, 17403
- WellSpan Health-York Hospital
-
York, Pennsylvania, Stati Uniti, 17408
- UPMC Memorial
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Medical University of South Carolina
-
Gaffney, South Carolina, Stati Uniti, 29341
- Gibbs Cancer Center-Gaffney
-
Georgetown, South Carolina, Stati Uniti, 29440
- Tidelands Georgetown Memorial Hospital
-
Greenville, South Carolina, Stati Uniti, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Stati Uniti, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Stati Uniti, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Stati Uniti, 29601
- Saint Francis Hospital
-
Greer, South Carolina, Stati Uniti, 29650
- Prisma Health Cancer Institute - Greer
-
Greer, South Carolina, Stati Uniti, 29651
- Gibbs Cancer Center-Pelham
-
Rock Hill, South Carolina, Stati Uniti, 29732
- Levine Cancer Institute-Rock Hill
-
Rock Hill, South Carolina, Stati Uniti, 29730
- Rock Hill Radiation Therapy Center
-
Seneca, South Carolina, Stati Uniti, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, Stati Uniti, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Stati Uniti, 29379
- SMC Center for Hematology Oncology Union
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Stati Uniti, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Germantown, Tennessee, Stati Uniti, 38138
- The West Clinic - Wolf River
-
Knoxville, Tennessee, Stati Uniti, 37920
- University of Tennessee - Knoxville
-
Nashville, Tennessee, Stati Uniti, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Amarillo, Texas, Stati Uniti, 79106
- The Don and Sybil Harrington Cancer Center
-
-
Utah
-
American Fork, Utah, Stati Uniti, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Farmington, Utah, Stati Uniti, 84025
- Farmington Health Center
-
Logan, Utah, Stati Uniti, 84321
- Logan Regional Hospital
-
Murray, Utah, Stati Uniti, 84107
- Intermountain Medical Center
-
Ogden, Utah, Stati Uniti, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Stati Uniti, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Stati Uniti, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Stati Uniti, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Stati Uniti, 84106
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City, Utah, Stati Uniti, 84143
- LDS Hospital
-
St. George, Utah, Stati Uniti, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Saint Johnsbury, Vermont, Stati Uniti, 05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Inova Schar Cancer Institute
-
Fairfax, Virginia, Stati Uniti, 22033
- Inova Fair Oaks Hospital
-
Portsmouth, Virginia, Stati Uniti, 23708-2197
- Naval Medical Center - Portsmouth
-
Richmond, Virginia, Stati Uniti, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Renton, Washington, Stati Uniti, 98055
- Valley Medical Center
-
Seattle, Washington, Stati Uniti, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Stati Uniti, 98122
- Swedish Medical Center-First Hill
-
Walla Walla, Washington, Stati Uniti, 99362
- Providence Saint Mary Regional Cancer Center
-
-
Wisconsin
-
Antigo, Wisconsin, Stati Uniti, 54409
- Aspirus Cancer Care-Antigo-Volm Cancer Center
-
Appleton, Wisconsin, Stati Uniti, 54915
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
-
Ashland, Wisconsin, Stati Uniti, 54806
- Duluth Clinic Ashland
-
Ashland, Wisconsin, Stati Uniti, 54806
- Northwest Wisconsin Cancer Center
-
Brookfield, Wisconsin, Stati Uniti, 53045
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
-
Burlington, Wisconsin, Stati Uniti, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Chilton, Wisconsin, Stati Uniti, 53014
- Ascension Calumet Hospital-Chilton
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- HSHS Sacred Heart Hospital
-
Franklin, Wisconsin, Stati Uniti, 53132
- Ascension Southeast Wisconsin Hospital - Franklin
-
Franklin, Wisconsin, Stati Uniti, 53132
- Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
-
Germantown, Wisconsin, Stati Uniti, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Stati Uniti, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Stati Uniti, 54311
- Aurora BayCare Medical Center
-
Green Bay, Wisconsin, Stati Uniti, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Stati Uniti, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Hayward, Wisconsin, Stati Uniti, 54843
- Essentia Health-Hayward Clinic
-
Johnson Creek, Wisconsin, Stati Uniti, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
Kenosha, Wisconsin, Stati Uniti, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Stati Uniti, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Stati Uniti, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Stati Uniti, 54143
- Aurora Bay Area Medical Group-Marinette
-
Menomonee Falls, Wisconsin, Stati Uniti, 53051
- Froedtert Menomonee Falls Hospital
-
Mequon, Wisconsin, Stati Uniti, 53097
- Ascension Columbia Saint Mary's Hospital-Ozaukee Campus-Mequon
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Stati Uniti, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Stati Uniti, 53233
- Aurora Sinai Medical Center
-
Milwaukee, Wisconsin, Stati Uniti, 53210
- Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee
-
Milwaukee, Wisconsin, Stati Uniti, 53211
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus
-
Milwaukee, Wisconsin, Stati Uniti, 53215
- Ascension Saint Francis Hospital-Milwaukee
-
Oshkosh, Wisconsin, Stati Uniti, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Oshkosh, Wisconsin, Stati Uniti, 54904
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
-
Racine, Wisconsin, Stati Uniti, 53406
- Aurora Cancer Care-Racine
-
Racine, Wisconsin, Stati Uniti, 53405
- Ascension All Saints Hospital-Spring Street-Racine
-
Rhinelander, Wisconsin, Stati Uniti, 54501
- Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
-
Sheboygan, Wisconsin, Stati Uniti, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Spooner, Wisconsin, Stati Uniti, 54801
- Essentia Health-Spooner Clinic
-
Stevens Point, Wisconsin, Stati Uniti, 54481
- Aspirus Cancer Care - Stevens Point
-
Summit, Wisconsin, Stati Uniti, 53066
- Aurora Medical Center in Summit
-
Superior, Wisconsin, Stati Uniti, 54880
- Essentia Health Saint Mary's Hospital - Superior
-
Two Rivers, Wisconsin, Stati Uniti, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wausau, Wisconsin, Stati Uniti, 54401
- Aspirus Cancer Care-Wausau
-
Wauwatosa, Wisconsin, Stati Uniti, 53226
- Aurora Cancer Care-Milwaukee West
-
Wauwatosa, Wisconsin, Stati Uniti, 53226
- Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
-
West Allis, Wisconsin, Stati Uniti, 53227
- Aurora West Allis Medical Center
-
West Bend, Wisconsin, Stati Uniti, 53095
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Wisconsin Rapids, Wisconsin, Stati Uniti, 54494
- Aspirus Cancer Care - Wisconsin Rapids
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma but not neuroendocrine phenotype) of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls); cytologic diagnosis from a cervical lymph node is sufficient in the presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence should be documented, may consist of palpation, imaging, or endoscopic evaluation, and should be sufficient to estimate the size of the primary (for T stage)
-
Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations. Simple tonsillectomy or local excision of the primary without removal of nodal disease is permitted, as is excision removing gross nodal disease but with intact primary site. Limited neck dissections retrieving =< 4 nodes are permitted and considered as non-therapeutic nodal excisions
-
P16-positive based on local site immunohistochemical tissue staining (defined as greater than 70% strong diffuse nuclear or nuclear and cytoplasmic staining of tumor cells). Fine needle aspiration (FNA) biopsy specimens may be used as the sole diagnostic tissue. Centers are encouraged to contact the pathology chair for clarification
- Note: Institutions must screen patients, whose tumors must be p16-positive by immunohistochemistry (IHC) in order to be eligible for the trial using a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. A rigorous laboratory accreditation process similar to the United States (U.S.) CLIA certification, such as the provincial accreditation status offered by the Ontario Laboratory Accreditation (OLA) Program in Canada, the College of American Pathologists (CAP), or an equivalent accreditation in other countries, is acceptable. The p16-positive results must be reported on the pathology report being submitted
- Note: If p16 result is equivocal, positive HPV deoxyribonucleic acid (DNA) test of tumor specimen is acceptable and fulfills the eligibility criteria
-
Clinical stage T1-2, N1, M0 (American Joint Committee on Cancer [AJCC], 8th edition [ed.]) or T3, N0-N1, M0 (AJCC, 8th ed.) including no distant metastases based on the following diagnostic workup:
-
General history and physical examination within 56 days prior to registration;
-
Exam with laryngopharyngoscopy (mirror or in office direct procedure acceptable) within 70 days prior to registration;
-
One of the following imaging studies is required within 56 days prior to registration:
- FDG-PET/CT of the neck and chest (with or without contrast); FDG-PET/CT scan is strongly preferred and highly recommended to be used for eligibility OR
- Chest CT (with or without contrast)
-
One of the following imaging studies is required within 28 days prior to registration:
- A diagnostic CT scan of neck (with contrast and of diagnostic quality) OR
- An magnetic resonance imaging (MRI) of the neck (with contrast and of diagnostic quality)
- Note: A diagnostic quality CT or MRI with contrast or FDG-PET/CT scan of neck performed for the purposes of radiation planning may serve as both staging and planning tools
-
-
Patients must provide their personal smoking history prior to registration. The lifetime cumulative history cannot exceed 10 pack-years. The following formula is used to calculate the pack-years during the periods of smoking in the patient's life; the cumulative total of the number of pack-years during each period of active smoking is the lifetime cumulative history
- Number of pack-years = [Frequency of smoking (number of cigarettes per day) x duration of cigarette smoking (years)] / 20
- Note: Twenty cigarettes is considered equivalent to one pack. The effect of non-cigarette tobacco products on the survival of patients with p16-positive oropharyngeal cancers is undefined. While there are reportedly increased risks of head and neck cancer associated with sustained heavy cigar and pipe use (Wyss 2013), such sustained use of non-cigarette products is unusual and does not appear to convey added risk with synchronous cigarette smoking. Cigar and pipe tobacco consumption is therefore not included in calculating the lifetime pack-years. Marijuana consumption is likewise not considered in this calculation. There is no clear scientific evidence regarding the role of chewing tobacco-containing products in this disease, although this is possibly more concerning given the proximity of the oral cavity and oropharynx. In any case, investigators are discouraged from enrolling patients with a history of very sustained use (such as several years or more) of non-cigarette tobacco products alone
-
Zubrod performance status of 0-1 within 14 days prior to registration
-
Age >= 18
-
Absolute neutrophil count >= 1,500/mcL (within 14 days prior to registration)
-
Platelets >= 100,000/mcL (within 14 days prior to registration)
-
Hemoglobin >= 8.0 g/dL (within 14 days prior to registration) (Note: use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dL is acceptable)
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 14 days prior to registration)
-
Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional ULN (within 14 days prior to registration)
-
Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (within 14 days prior to registration)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Note: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B)
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment for the hepatitis, they are eligible if they have an undetectable HCV viral load.
- Note: Known positive test for hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy
-
For women of childbearing potential (WOCBP), negative serum or urine pregnancy test within 24 hours prior to registration
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL
-
Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception during and after treatment
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
-
Only English, Spanish, or French speaking patients are eligible to participate as these are the only languages for which the mandatory dysphagia-related patient reported instrument (MDADI) is available
Exclusion Criteria:
-
Clinical stages T0; T4; T1-2, N0; or any N2 (AJCC, 8th ed)
-
Recurrent disease
-
Definitive clinical or radiologic evidence of metastatic disease or adenopathy below the clavicles
-
Cancers considered to be from an oral cavity site (oral tongue, floor mouth, alveolar ridge, buccal or lip), or the nasopharynx, hypopharynx, or larynx, even if p16-positive, or histologies of adenosquamous, verrucous, or spindle cell carcinomas
-
Carcinoma of the neck of unknown primary site origin (T0 is ineligible, even if p16-positive)
-
Radiographically matted nodes, defined as 3 abutting nodes with loss of the intervening fat plane
-
Supraclavicular nodes, defined as nodes centered below the level of the cricoid cartilage
-
Gross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease. In other words, to participate in this protocol, the patient must have clinically or radiographically evident gross disease for which disease response can be assessed
-
Patients with simultaneous primary cancers or separate bilateral primary tumor sites are excluded with the exception of patients with bilateral tonsil cancers
-
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) (of note, the exclusion applies only for invasive cancers such that carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
-
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
-
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
-
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
-
History of severe hypersensitivity reaction to any monoclonal antibody.
-
Severe, active co-morbidity defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
- Transmural myocardial infarction within the last 6 months
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
- Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition with immune compromise greater than that noted; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients
- Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of registration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
- Patients with active autoimmune disease requiring systemic treatment (i.e. disease modifying agents, corticosteroids, or immunosuppressive drugs) should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease
- Note: Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)
-
Patients who are pregnant, nursing, or expecting to conceive or father children
-
Prior allergic reaction to cisplatin
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Arm I (Standard RT + cisplatin)
Patients undergo standard dose RT as 70 Gy IMRT or IGRT over 6 fractions per week and receive 100 mg/m^2/day cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study. |
Ancillary studies
Altri nomi:
Given IV
Altri nomi:
Undergo blood sample collection
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Ancillary studies Undergo PET
Altri nomi:
Undergo IMRT
Altri nomi:
Receive FDG
Altri nomi:
Undergo tissue biopsy
Altri nomi:
Undergo IGRT
Altri nomi:
|
|
Sperimentale: Arm II (Reduced RT + cisplatin)
Patients undergo reduced dose RT as 60 Gy IMRT or IGRT QD over 5 fractions per week and receive 100 mg/m^2/day cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study. |
Ancillary studies
Altri nomi:
Given IV
Altri nomi:
Undergo blood sample collection
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Ancillary studies Undergo PET
Altri nomi:
Undergo IMRT
Altri nomi:
Receive FDG
Altri nomi:
Undergo tissue biopsy
Altri nomi:
Undergo IGRT
Altri nomi:
|
|
Sperimentale: Arm III (Reduced RT + nivolumab)
Beginning 1 week prior to radiation, patients receive 240 mg fixed dose nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks (14 days) for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo reduced dose RT as 60 Gy IMRT or IGRT over 6 fractions per week for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study. |
Ancillary studies
Altri nomi:
Undergo blood sample collection
Altri nomi:
Undergo CT
Altri nomi:
Ancillary studies Undergo PET
Altri nomi:
Given IV
Altri nomi:
Undergo IMRT
Altri nomi:
Receive FDG
Altri nomi:
Undergo tissue biopsy
Altri nomi:
Undergo IGRT
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free Survival (PFS) (Phase II) (Percentage of Participants Alive Without Progression)
Lasso di tempo: From randomization to first progression or last follow-up. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
Progression is defined as local-regional progression or recurrence, distant metastasis, death due to any reason, salvage surgery of primary with tumor present/unknown, salvage neck dissection with tumor present/unknown, > 20 weeks from end of radiation therapy. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis. The primary phase IIR endpoint is tested using a confidence interval (CI) approach with each experimental arm compared to the standard arm (Arm 1). |
From randomization to first progression or last follow-up. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
|
Progression-free Survival (Phase III) (Percentage of Participants Alive Without Progression)
Lasso di tempo: From randomization to first progression or last follow-up. Maximum follow-up was 4.6 years.
|
Progression is defined as local-regional progression or recurrence, distant metastasis, death due to any reason, salvage surgery of primary with tumor present/unknown, salvage neck dissection with tumor present/unknown, > 20 weeks from end of radiation therapy. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis. |
From randomization to first progression or last follow-up. Maximum follow-up was 4.6 years.
|
|
MD Anderson Dysphagia Inventory (MDADI) Global Quality of Life (QOL) Score
Lasso di tempo: Baseline to two years
|
The M. D. Anderson Dysphagia Inventory (MDADI) assesses how patients view their swallowing ability as a result of treatment and how this affects their QOL. It consists of a global quality of life question and a functional, emotional, and physical subscale. The global QOL question ranges from 1 to 5 and multiplied by 20 to obtain a score with a range of 0 to 100. Higher scores indicate better functioning. |
Baseline to two years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Locoregional Failure (Percentage of Participants With Locoregional Failure)
Lasso di tempo: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
Locoregional failure is defined as local-regional progression or recurrence, death due to study cancer or unknown causes, salvage neck dissection with tumor present/unknown. Locoregional failure rates are estimated the cumulative incidence method, treating distant metastasis and death due to any reason other than study cancer or unknown as competing risks, and otherwise censoring participants alive at time of analysis. Each experimental arm is compared to the standard arm (Arm I). |
From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
|
Distant Failure (Percentage of Participants With Distant Failure)
Lasso di tempo: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
Distant failure is defined as the occurrence of distant metastasis. Distant failure rates are estimated the cumulative incidence method, treating local-regional progression or recurrence, death due to any reason, salvage neck dissection with tumor present/unknown as competing risks, and otherwise censoring participants alive at time of analysis. Each experimental arm is compared to the standard arm (Arm I). |
From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
|
Overall Survival (Percentage of Participants Alive)
Lasso di tempo: From randomization to death from any cause or last follow-up. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis. |
From randomization to death from any cause or last follow-up. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
|
Number of Participants by Highest Grade Adverse Event Reported
Lasso di tempo: From randomization to last known follow-up. Maximum follow-up at the time of analysis was 4.6 years.
|
Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From randomization to last known follow-up. Maximum follow-up at the time of analysis was 4.6 years.
|
|
Hearing
Lasso di tempo: Baseline up to 24 months from end of radiation therapy (RT)
|
Measured as Hearing Handicap Inventory for Adults-Screening (HHIA-S). |
Baseline up to 24 months from end of radiation therapy (RT)
|
|
Quality of Life
Lasso di tempo: Baseline up to 24 months from end of RT
|
Measured by the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire (QLQ)30. |
Baseline up to 24 months from end of RT
|
|
Fludeoxyglucose F-18 (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) Locoregional Control
Lasso di tempo: Up to 6 years
|
Will be associated with PFS. |
Up to 6 years
|
|
Negative Predictive Value of Post-RT FDG-PET/CT for Locoregional Control
Lasso di tempo: At 1 and 2 years
|
The negative predictive value of FDG-PET/CT for locoregional control will be estimated using binomial proportions and confidence intervals based on normal approximation. |
At 1 and 2 years
|
|
Negative Predictive Value of Post-RT FDG-PET/CT for PFS
Lasso di tempo: At 1 and 2 years
|
The negative predictive value of FDG-PET/CT PFS will be estimated using binomial proportions and confidence intervals based on normal approximation. |
At 1 and 2 years
|
|
Incidence of Adverse Events
Lasso di tempo: Up to 6 years
|
Measured using Patient-Reported Outcomes (PRO)-CTCAE. For each symptom, counts and frequencies will be provided for the worst score experienced by the patient by treatment arm. The proportion of patients with scores >= 1 and >= 3 will be compared between groups using a Chi-square test, or Fisher's exact test if cell frequencies are < 5, using a significance level of 0.05. Analysis of changes in patient reported outcomes over time will analyzed by fitting generalized estimating equations (GEE) models using a logit link (dichotomizing the symptom scores as 0 vs. > 1 and 0-2 vs. 3-4) with time of assessment, treatment arm, and treatment-by-time interaction terms in the model. |
Up to 6 years
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Quality of Life
Lasso di tempo: Baseline up to 24 months from end of RT
|
Measured by EuroQol-5 Dimensional- 5 Level (EQ-5D-5L). |
Baseline up to 24 months from end of RT
|
|
Swallowing Physiology
Lasso di tempo: Up to 6 years
|
Measured by a Modified Barium Swallow (MBS) test. The proportion of aspiration for each arm will be estimated assuming a binomial distribution and between arm comparison will be performed using a Fisher's exact test. |
Up to 6 years
|
|
Locoregional Control for Patients With Post-RT FDG-PET/CT
Lasso di tempo: At 12-14 weeks post-RT
|
Locoregional control rates will be compared between negative and positive/undetermined patients. Cox proportional hazards models will be used to determine whether there are differences between these two groups, while adjusting for treatment arm and other covariates (cause-specific Cox models for locoregional failure). |
At 12-14 weeks post-RT
|
|
PFS for Patients With Post-RT FDG-PET/CT
Lasso di tempo: At 12-14 weeks post-RT
|
PFS rates will be compared between negative and positive/undetermined patients. Cox proportional hazards models will be used to determine whether there are differences between these two groups, while adjusting for treatment arm and other covariates (cause-specific Cox models for locoregional failure). |
At 12-14 weeks post-RT
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Sue S Yom, NRG Oncology
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie stomatognatiche
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Carcinoma
- Neoplasie, cellule squamose
- Malattie otorinolaringoiatriche
- Neoplasie faringee
- Neoplasie otorinolaringoiatriche
- Malattie faringee
- Carcinoma a cellule squamose della testa e del collo
- Carcinoma, cellule squamose
- Neoplasie orofaringee
- Aminoacidi, peptidi e proteine
- Proteine
- Tecniche investigative
- Terapie
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Procedure chirurgiche, operative
- Tecniche citologiche
- Citodiagnosi
- Carboidrati
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Elementi
- Metalli
- Tecniche diagnostiche, chirurgiche
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Metalli, pesante
- Composti di platino
- Radioterapia
- Deossiglucosio
- Zuccheri di desossi
- Elementi di transizione
- Radioterapia, conforme
- Radioterapia, assistita da computer
- Nivolumab
- Fluorodesossiglucosio F18
- Cisplatino
- 1,2-diamminocicloesaneplatino II citrato
- Biopsia
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- Platino
- Radioterapia, modulata intensità
- Radioterapia, guidata dall'immagine
Altri numeri di identificazione dello studio
- NCI-2019-03015
- U10CA180868 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2019-03015 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- NRG-HN005 (Altro identificatore: CTEP)
- NRG-HN005 (Altro identificatore: NRG Oncology)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .